An Open-Label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients With Metachromatic Leukodystrophy
Phase of Trial: Phase I/II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Cerebroside-sulfatase (Primary)
- Indications Metachromatic leukodystrophy
- Focus Adverse reactions
- Sponsors Shire
- 21 Aug 2015 Protocol has been amended to change in treatment arms.
- 21 Aug 2015 Planned End Date changed from 1 Feb 2018 to 1 Oct 2021 as reported by ClinicalTrials.gov record.
- 21 Aug 2015 Planned primary completion date changed from 1 Feb 2018 to 1 Oct 2021 as reported by ClinicalTrials.gov record.